

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Exagamglogene autotemcel for treating sickle cell disease

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following equality issues were raised during consultation:

- sickle cell disease mainly affects people from African or African-Caribbean family background
- there is a socioeconomic imbalance among people with sickle cell disease.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Where appropriate, the committee will consider the impact the recommendations may have for people with protected characteristics (including race) and the impact on people from socioeconomically deprived backgrounds

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The consultation version of the scope included reference to the high prevalence of sickle cell disease in people of African or African-Caribbean family background. Therefore, no changes have been made to the scope to

address this issue. Other issues have not been referenced in the scope but will be considered by the committee.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

Yes. The African Caribbean Leukaemia Trust, UK National Haemoglobinopathy Panel and Caribbean and African Health Network have been added as consultees.

Approved by Associate Director (name): Jasdeep Hayre **Date:** 6 June 2023